A multiple ascending dosing study of PC-mAb in healthy volunteers.
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
Price : $35 *
At a glance
- Drugs PC mAb (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Coronary artery restenosis
- Focus Adverse reactions
- 29 Aug 2017 New trial record
- 30 Jan 2016 According to an Athera Biotechnologies media release, dosing has been initiated in this trial.